RxDoctor Payments Data

Mavis Billips, MD

Dermatology · Los Angeles, CANPI 1902905664

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (47.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Regeneron at 42.9% of the total.

$11,334in general payments, 2019–2025

Across 286 payments — averaging $39.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$5K
  • Pfizer$2K
  • UCB, Inc.$833
  • 3M Company$500
  • Incyte Corporation$418
  • Sanofi$393
  • plus $3K from 23 others
$30,470in research payments, 2019–2025

Across 8 payments — averaging $3808.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$30K

What the payments were for

  • Consulting fees$5,35747%
  • Travel & lodging$5815%
  • Food & beverage$5,28447%
  • Education$1121%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,334 in reported general payments places this provider in the 80th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California →

Medicare billing

Part B allowed, 2024
$17,870
Medicare patients
43
Services billed
146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab11$55,282
Fluorouracil99$6,324
Tacrolimus26$3,241
Ketoconazole41$753
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc15$689
Tretinoin11$661
Fluocinolone Acetonide12$442
Ciclopirox16$340
Clindamycin Phosphate17$297
Fluocinolone AcetonideFluocinolone/Shower Cap12$295
Triamcinolone Acetonide29$280
Hydrocortisone41$188
Minoxidil26$173
Hydroxyzine Hcl11$49

Paid to pharmacies, not to this prescriber.

Other dermatology in Los Angeles

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →